1Johannsson G,Albertsson-wikland K.Discontinuation of growth hormone (GH) treatment metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects.J Clin Endocrinol Metab,1999,84(12):4516-4524.
2Watanabe S,Mizuno S,Oshima LH,et al.Leukemia and other malignancies among GH users.J Pediatr Endocrinol,1993,6(1):99-108.
3Blethen SL,Allen DB,Graves D,et al.Safety of recombinant deoxyribonucleic acid-derived growth hormone:the National Cooperative Growth Study experience.J Clin Endocrinol Metab,1996,81(5):1704-1710.
4Blethen SL.Leukemia in children treated with growth hormone.TEM,1998,9(9):367-370.
5Jenkins PJ,Fairclough PD,Richards T,et al.Acromegaly colonic polyps and carcinoma.Clin Endocrinol,1997,47(1):17-22.
6Swerdlow AJ,Higgins CD,Adlard P,et al.Risk of cancer in patients treated with human pituitary growth hormone in the UK,1959-85:a cohort study.Lancet,2002,360(9329):273-277.
7Weiss-Messer Esther,Merom O,Adi A,et al.Growth hormone (GH) receptors in prostate cancer:gene expression in human tissue and cell lines and characterization,GH signaling and androgen receptor regulation in LNCaP cells.Mol Cell Endocrin,2004,220(1):109-123.
8Sklar CA,Mertens AC,Mitby P,et al.Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone:a report from the childhood cancer survivor study.J Clin Endocrinol Metab,2002,87(7):3136-3141.
9Chan JM,Stampfer MJ,Giovannucci E,et al.Plasma insulin-like growth factor-I and prostate cancer risk:a prospective study.Science,1998,279(5350):563-566.
10Chan JM,Stampfer MJ,Ma J,et al.Insulin-like growth factor-I (IGF-1) and IGF binding protein-3 as predictors of advanced-stage prostate cancer study.J Natl Cancer Inst,2002,94(14):1099-1106.
